HIV type-1 group O infection in Gabon: Low prevalence rate but circulation of genetically diverse and drug-resistant HIV type-1 group O strains

AIDS Research and Human Retroviruses

Volumn 29, Issue 7, 2013, Pages 1085-1090

  Liégeois, Florian ^a,b   Boué, Vanina ^a   Butel, Christelle ^b   Mouinga Ondémé, Augustin ^a   Sica, Jeanne ^c   Zamba, Chantal ^c   Peeters, Martine ^b   Delaporte, Eric ^b   Rouet, François ^a  

^a CENTRE INTERNATIONAL DE RECHERCHES MÉDICALES DE FRANCEVILLE   (Gabon)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c Centre de Traitement Ambulatoire (CTA)   (Gabon)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 41; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FOLLOW UP; GABON; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GABON; GENETIC VARIATION; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHYLOGENY; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84879185872     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0375     Document Type: Article

References (20)

1. Hemelaar J: The origin and diversity of the HIV-1 pandemic. Trends Mol Med 2012;18:691-694.
2. Vessiere A, Rousset D, Kfutwah A, et al.: Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroon. J Acquir Immune Defic Syndr 2010;53:107-110.
3. Peeters M, Gueye A, Mboup S, et al.: Geographic distribution of HIV-1 group O viruses in Africa. AIDS 1997;11:493-498.
4. Liegeois F, Vella C, Eymard-Duvernay S, et al.: Virological failure rates and HIV-1 drug resistance patterns in patients on first-line antiretroviral treatment in semirural and rural Gabon. J Int AIDS Soc 2012;15:179-185.
5. Descamps D, Collin G, Letourneur F, et al.: Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: In vitro phenotypic and genotypic analyses. J Virol 1997;71:8893-8898.
6. Tuaillon E, Gueudin M, Lemee V, et al.: Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr 2004;37:1543-1549.
7. Simon F, Souquiere S, Damond F, et al.: Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses. AIDS Res Hum Retroviruses 2001;17:937-952.
8. Tamura K, Dudley J, Nei M, et al.: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596-1599.
9. Milne I, Lindner D, Bayer M, et al.: TOPALi v2: A rich graphical interface for evolutionary analyses of multiple alignments on HPC clusters and multi-core desktops. Bioinformatics 2009;25:126-127.
10. Guindon S, Dufayard JF, Lefort V, et al.: New algorithms and methods to estimate maximum-likelihood phylogenies: Assessing the performance of PhyML 3.0. Syst Biol 2010;59: 307-321.
11. Yamaguchi J, Vallari AS, Swanson P, et al.: Evaluation of HIV type 1 group O isolates: Identification of five phylogenetic clusters. AIDS Res Hum Retroviruses 2002;18:269-282.
12. Roques P, Robertson DL, Souquiere S, et al.: Phylogenetic analysis of 49 newly derived HIV-1 group O strains: High viral diversity but no group M-like subtype structure. Virology 2002;302:259-273.
13. Yamaguchi J, Bodelle P, Vallari AS, et al.: HIV infections in Northwestern Cameroon: Identification of HIV type 1 group O and dual HIV type 1 group M and group O infections. AIDS Res Hum Retroviruses 2004;20:944-957.
14. Rodes B, de Mendoza C, Rodgers M, et al.: Treatment response and drug resistance in patients infected with HIV type 1 group O viruses. AIDS Res Hum Retroviruses 2005;21:602-607.
15. Depatureaux A, Charpentier C, Leoz M, et al.: Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M. J Acquir Immune Defic Syndr 2011;56:139-145.
16. Luk K-C, Kaptué L, Zekeng L, et al.: Naturally occurring sequence polymorphisms within HIV type 1 group O protease. AIDS Res Hum Retroviruses 2001;17:1555-1561.
17. Depatureaux A, Charpentier C, Collin G, et al.: Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide. Antimicrob Agents Chemother 2010;54:4016-4019.
18. Ghosn J, Delaugerre C, Flandre P, et al.: Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. PLoS One 2011;6:e24798.
19. Leoz M, Depatureaux A, Vessière A, et al.: Integrase polymorphism and HIV-1 group O diversity. AIDS 2008;22:1239-1243.
20. Aghokeng AF, Kouanfack C, Peeters M, et al.: Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class- resistant HIV type 1 group O-infected patient in Cameroon. AIDS Res Hum Retroviruses 2013;29:1-3.